Last edition
News about "phase III FENtrepid trial"
Roche's Fenebrutinib Matches Ocrevus in Slowing Disability Progression in PPMS Phase III Trial
Phase III FENtrepid study shows oral BTK inhibitor fenebrutinib achieved non-inferiority to Ocrevus in primary progressive multiple sclerosis, reducing disability progression risk by 12 percent with consistent subgroup benefit.
Phase III FENtrepid Trial | 10/02/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members